Results 41 to 50 of about 188,223 (344)
Pharmaceuticals, 2014 Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources.
William H. Baer II +2 more
doaj +1 more source
Glomerular Diseases, 2023 Background: Minimal change disease and primary FSGS are podocytopathies but are also immune-mediated diseases. Rituximab acts via multiple mechanisms by tilting the balance between autoreactive B & T cells in favor of regulatory B & T cells.
Ahsan Aslam, Abbal Koirala
doaj +1 more source
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. [PDF]
, 2017 BACKGROUND: Median age at diagnosis of patients with chronic lymphocytic leukemia (CLL) is \u3e 70 years. However, the majority of clinical trials do not reflect the demographics of CLL patients treated in the community.
Bhushan, Shriya +12 more
core +3 more sources
Actas Dermo-Sifiliográficas (English Edition), 2013 Rituximab was introduced into clinical practice as a medication with considerable potential. Its use in patients with B-cell lymphoma and rheumatoid arthritis revealed numerous indications in autoimmune diseases, many of which involve the skin, thus requiring dermatologists to become familiar with both the characteristics of anti-CD20 antibodies and ...
Agustín España +2 more
openaire +3 more sources
Annals of the Rheumatic Diseases, 2005 Rituximab is a chimeric monoclonal antibody that was developed for the treatment of B cell lymphomas.1 It is directed against the CD20 cell surface molecule.2 CD20 is a tetraspan membrane protein that is present only on B cells, and is expressed initially at the immature B cell stage, remaining until the final differentiation into plasma cells.
openaire +3 more sources
Rituximab-induced toxicity [PDF]
QJM, 2010 A 80-year-old woman with relapsing, idiopathic thrombocytopenic purpura was admitted because of diffuse cutaneous and mucosal petechiae and ecchimoses; no sign of visceral bleeding was noted. A marrow aspirate confirmed the absence of morphologic abnormalities in the blood cell precursor lineages. Blood counts revealed Hb 14.5 mg/dl and platelets 1000 ×
Mumoli, N., Cei, M.
openaire +4 more sources
Journal of the American College of Cardiology, 2013 Rituximab is a recombinant, anti-CD20 antibody that has emerged in recent years as an effective therapy for non-Hodgkin's lymphoma and other B-cell malignancies. Data examining the cardiovascular toxicities of rituximab are scant, even though various cases of fulminant heart failure have ...
Carolina D. Schinke +5 more
openaire +2 more sources
Rituximab for Rheumatoid Arthritis
Rheumatology and Therapy, 2015 Rituximab is a chimeric monoclonal antibody directed at the CD20 molecule on the surfaces of some but not all B cells. It depletes almost all peripheral B cells, but other niches of B cells are variably depleted, including synovium. Its mechanism of action in rheumatoid arthritis (RA) is only partially understood.
Edward C. Keystone +2 more
openaire +6 more sources
Turkish Journal of Hematology, 2017 Objective: This paper prospectively evaluates the long-term followup [mean +- standard deviation (SD) duration: 89.7+-19.4 months] data of 15 patients (13 females and 2 males) with refractory symptomatic immune thrombocytopenia (ITP) treated with ...
Fehmi Hindilerden +4 more
doaj +1 more source
BMC Nephrology, 2020 Background Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving perioperative treatment with rituximab, which is associated with ...
Young Hoon Kim +10 more
doaj +1 more source